Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed No phase listed Observational

The Physiology of Fatigue in Patients With Chronic Liver Disease

NCT01867385
View directory record Official record
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 23, 2026, 10:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comparison of ALD, NASH, and Healthy Control Patients

NCT03224949
View directory record Official record
Conditions
ALD - Alcoholic Liver Disease
Interventions
Blood draw
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 3 Interventional

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

NCT00411385
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

NCT00926146
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions
NCMIT, SCMIT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
451 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

NCT02184572
View directory record Official record
Conditions
Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,742 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
80
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 23, 2026, 10:11 PM EDT
Active, not recruiting Not applicable Interventional

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT06316739
View directory record Official record
Conditions
HIV Infections, HCV, Overdose
Interventions
Ganchero intervention
Behavioral
Lead sponsor
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 10:11 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

NCT06745895
View directory record Official record
Conditions
Colorectal Cancer Screening, Hepatitis C Virus
Interventions
MATCHES
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
45 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

NCT00410072
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Entecavir + Tenofovir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

NCT01671787
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
GS-7340, Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Not applicable Interventional Results available

Helping Empower Liver and Kidney Patients

NCT03426787
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Diseases, Patient Education
Interventions
Decision Aid
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 23, 2026, 10:11 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

DV2-HBV-27: Observational Pregnancy Registry

NCT03664648
View directory record Official record
Conditions
Pregnant
Interventions
HEPLISAV-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 4 Interventional

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

NCT00275548
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
Pegasys, Copegus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

NCT03057847
View directory record Official record
Conditions
Hepatitis C, Chronic, Opioid-use Disorder
Interventions
Sofosbuvir/Velpatasvir
Drug
Lead sponsor
Elizabeth Krans, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 3 Interventional Results available

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

NCT00483938
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Pegylated-interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 23, 2026, 10:11 PM EDT
Completed No phase listed Observational

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

NCT02006823
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection

NCT03312023
View directory record Official record
Conditions
Hepatitis B
Interventions
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 2 Interventional

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

NCT00983060
View directory record Official record
Conditions
Chronic Hepatitis C Genotype-1 Relapse
Interventions
NIM811, Placebo BID + SOC
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
San Diego, California • Orlando, Florida • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Not applicable Interventional Results available

Criminal Justice Coordinated Transitional Care

NCT05376371
View directory record Official record
Conditions
HIV, Hepatitis C, Substance Use Disorders
Interventions
CJC-TraC
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Oregon, Wisconsin • Union Grove, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 23, 2026, 10:11 PM EDT
Terminated No phase listed Observational Results available

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

NCT01182298
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 23, 2026, 10:11 PM EDT
Not listed Not applicable Interventional

Implementing HCV Treatment for High-risk Populations in Austin, Texas

NCT05460130
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simplified Hepatitis C Virus (HCV) Treatment Protocol
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 23, 2026, 10:11 PM EDT
Terminated Phase 2 Interventional

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

NCT00228592
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepeX-B, Hepatitis B Immune Globulin (HBIg)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 1 Interventional

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fecal Microbiota Transplantation in Pediatric Patients

NCT02108821
View directory record Official record
Conditions
Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 22 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 23, 2026, 10:11 PM EDT
Completed Phase 1 Interventional Results available

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

NCT01525628
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 23, 2026, 10:11 PM EDT